

SB16 (2023)

Transgender Medical Treatments and Procedures Amendments Progress Report

Michelle Hofmann, MD, MPH, MHCDS
Executive Medical Director
Deputy Director, Clinical Services Section

Purpose

DHHS, in consultation with DOPL, the Physicians Licensing Board, the Osteopathic Physician and Surgeon's Licensing Board, the University of Utah, and a non-profit hospital system with... experience in specialty pediatric care, shall conduct a **systematic medical evidence review** regarding the provision of hormonal transgender treatments to minors

Section 26B-1-239

Advisors:

William Francis, DO - family medicine

Alan Smith, MD - family medicine

Angelo Giardino, MD, PhD, MPH - pediatrics and child abuse pediatrics

Brooks Keeshin, MD - child psychiatrist, child abuse pediatrician, clinician researcher

Nikki Mihalopoulos, MD, MPH - adolescent medicine, preventive cardiology

Katherine Smith, PharmD - pharmacist

DHHS representatives:

Michelle Hofmann, MD, MPH, MHCDS - pediatrician

Jennifer Strohecker, PharmD - pharmacist

Yoon Kim-Butterfield, MD - internal medicine, endocrinology


University of Utah Drug Regimen Review Center (DRRC):

Joanne LaFleur, PharmD, MSPH - pharmacist, director

Tami Haines, PharmD - pharmacist

Kristin Knippenberg, MFA - project administration

Contractor



SB16 (2023)
effective

January 28, 2023

DRRC early
draft report
available for
DHHS review

July 31, 2023

Advisors
convened for
preliminary
review of DRRC
report

January 2024

DRRC presents
long-term
outcomes to
advisors

June 6, 2024

Present final
recommendations
to HHS interim

August 2024

DRRC initiates
systematic
medical evidence
review

April 2023

DHHS begins
recruiting
advisors

August 16, 2023

DRRC presents
to advisors;
request for
additional
long-term data

February 2024

Reconvene
advisors to build
consensus

June 20, 2024

Study criteria

- **Population**

- Transgender individuals who started hormone treatment before 18 years of age
- Long-term studies: ≥ 5 years of follow-up after hormonal treatment

- **Intervention / exposure**

- Hormone and hormone-blocking agents

- **Publication type**

- Guidelines
- Clinical studies
 - Systematic reviews
 - Experimental studies
 - Observational studies
 - Descriptive studies
 - Case studies / reports

Study criteria

- **High priority comparisons**
 - Before and after hormone treatment
 - Transgender with and without hormone treatment
 - Transgender compared to cisgender
- **High priority outcomes**
 - Mental health, psychosocial functioning, gender dysphoria
 - Bone health, cardiovascular health, cancer
 - Regret
 - Mortality (long-term studies only)

Initial systematic medical evidence review:

277 full-text citations

28,056 pediatric gender dysphoria patients from around the world

Published 2010 or after

Additional study of long-term outcomes:

27 full-text citations

10,147 gender dysphoria patients from Europe and United States

Published 2010 or after

Purpose

The purpose of the systematic medical evidence review is to provide the Legislature with **recommendations to consider when deciding whether to lift the moratorium** described in Section 26B-1-239.